<DOC>
	<DOCNO>NCT00569465</DOCNO>
	<brief_summary>It demonstrate nitric oxide production reduce type 2 diabetic patient cardiovascular complication represent 80 % cause death patient . As nitric oxide able reduce platelet aggregation , increase relaxation smooth muscle cell , reduce plasminogen activator inhibitor-1 endothelin , hypothesize nitric oxide deficiency responsable cardiovascular disease type 2 diabetes mellitus . Arginine N-acetylcysteine , precursor enhancer nitric oxide synthesis respectively , able increase nitric oxide production . Aim study evaluate effect arginine N-acetylcysteine administration arterial blood pressure different metabolic parameter patient type 2 diabetes mellitus hypertension . Subjects method . 24 male subject , randomly divide two group , study . These subject undergo treatment arginine ( 1200 mg day ) plus N-acetylcysteine ( 600 mg twice day ) placebo six month . Basal final evaluation include : - general examination - ABPM ( ambulatory blood pressure monitoring ) - HbA1c , total-cholesterol , HDL-cholesterol , LDL-cholesterol , oxidize LDLs , triglyceride , reduced/oxidized glutathione ratio red blood cell , nitrites/nitrates , asymmetrical symmetrical dimethyl-arginine , nitrotyrosine , arginine , homocysteine , C-reactive protein , interleukin-6 , tumor necrosis factor-Î± , intercellular vascular-cell adhesion molecule , plasminogen activator inhibitor-1 fibrinogen - ultrasound assessment intima-media thickness endothelium-dependent flow-mediated vasodilation brachial artery Expected result . Increase nitric oxide production reduction arterial blood pressure oxidative parameter .</brief_summary>
	<brief_title>N-Acetylcysteine Arginine Administration Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Male subject Age 40 70 year Type 2 diabetes mellitus hypertension Mean 24h arterial blood pressure washout period : systolic &gt; 136mmHg and/or diastolic &gt; 86 mmHh Written inform consent Female subject Mean 24h arterial blood pressure washout period : systolic &gt; 180 mmHg and/or diastolic &gt; 110 mmHg Secondary hypertension Significative cardiovascular complication diabetes Cancer severe systemic , hepatic , pulmonary , cardiovascular disease Actual treatment nitrate , acetylcysteine arginine Acetylcysteine hypersensitivity Psychiatric disturbs , abuse drug alcohol Low compliance Absence write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>nitric oxide</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>diabetes</keyword>
	<keyword>hypertension</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>